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Intercellular communication is essential for the development of specialized cells, tissues,
and organs and is critical in a variety of diseases including cancer. Current knowledge
states that different cell types communicate by ligand–receptor interactions: hormones,
growth factors, and cytokines are released into the extracellular space and act on
receptors, which are often expressed in a cell-type-specific manner. Non-coding RNAs
(ncRNAs) are emerging as newly identified communicating factors in both physiological
and pathological states. This class of RNA encompasses microRNAs (miRNAs, well-
studied post-transcriptional regulators of gene expression), long non-coding RNAs
(lncRNAs) and other ncRNAs. lncRNAs are diverse in length, sequence, and structure
(linear or circular), and their functions are described as transcriptional regulation,
induction of epigenetic changes and even direct regulation of protein activity. They
have also been reported to act as miRNA sponges, interacting with miRNA and
modulating its availability to endogenous mRNA targets. Importantly, lncRNAs may have
a cell-type-specific expression pattern. In this paper, we propose that lncRNA–miRNA
interactions, analogous to receptor–ligand interactions, are responsible for cell-type-
specific outcomes. Specific binding of miRNAs to lncRNAs may drive cell-type-specific
signaling cascades and modulate biochemical feedback loops that ultimately determine
cell identity and response to stress factors.
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INTRODUCTION
Cancer is a complex disease and a major cause of death worldwide. Development of neoplastic
disease is a multistep process involving the accumulation of numerous molecular changes. These
changes impact cellular function within the tumor and its microenvironment, ultimately resulting
in the hallmarks of cancer (Hanahan and Weinberg, 2011).
To date, most researchers have aimed to define the molecular mechanisms of tumorigenesis
and cancer progression based on the classical gene expression theory – transcription of coding
genes followed by protein synthesis. Following this approach, numerous genetic (e.g., mutations
and genomic aberrations) and epigenetic alterations have been identified to have an association
with carcinogenesis (Lengauer et al., 1998; Kagohara et al., 2018). In addition, alterations in
post-transcriptional regulation of gene expression (e.g., splicing), mRNA translation (e.g., miRNAs)
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and post-translational protein modification (e.g., phosphory-
lation) have been reported in almost every type of cancer.
When different combinations are taken into consideration, the
potential alterations are almost infinite. However, studies have
mainly been based on around 20,000 protein-coding genes,
corresponding to approximately 2% of the whole transcribed
genome (Bertone et al., 2004; Carninci et al., 2005); the other
transcripts include a large variety of non-coding RNAs (ncRNAs).
Continuous generation of RNA sequencing (RNAseq) data shows
that ncRNAs are strongly deregulated in pathological processes –
particularly in multifactorial diseases like cancer (Cipolla et al.,
2018). Hence, current limitations to deciphering the molecular
mechanisms of cancer might be due to the fact that the putative
implications of a large part of the genome remain undefined.
While ncRNA genes were for years considered as an irrelevant
part the genome there is growing evidence that mammalian cells
produce them in their thousands (Bertone et al., 2004; Carninci
et al., 2005). Yet, in the absence of experimental verification
of their function, most (>95%) of these transcripts are still
considered transcriptional noise (Ponjavic et al., 2007). Studies
dating back to the early 1990s indicated that certain lncRNAs
may have similar functions to common mRNAs (Brannan et al.,
1990; Brown et al., 1991), and since then, detailed studies on
certain well-characterized non-coding transcripts have provided
mechanistic insights. However, the variety in their mode of
action, ranging from protein activity regulation to epigenetic
control and regulation of other ncRNAs, implies that we are
just beginning to understand their importance for a multitude
of biochemical and cellular functions. Importantly, the role of
these transcripts in certain tumor types is beginning to become
apparent, and lncRNA expression profile has been proposed as
a strong prognostic factor (Jiang et al., 2016; Bolha et al., 2017;
Ali et al., 2018). It is therefore conceivable that elucidating the
function of lncRNAs in normal cells and their deregulation in
cancer cells will be one of the next milestones toward a more
detailed understanding of the molecular mechanisms of cancer.
In this review, we propose a new role of ncRNAs in cancer.
This model, analogous to the well-established ligand–receptor
interactions, proposes intercellular communication via ncRNA
interactions as a fundamental concept in cancer. This model
could provide a hypothetical basis to explain the different types
of biochemical feedback in tissues, which in turn could be linked
to the differing response to drugs in tumors harboring similar
genetic alterations, the different sites of tumor metastases, and
the activation of different microRNA profiles depending on the
tumor type and location.
THE NON-CODING TRANSCRIPTOME
RNAs comprise a diverse range of molecules. In addition to
the well-characterized RNAs with established functions such
as coding genes (mRNAs), protein synthesis (rRNAs and
tRNAs), or mRNA splicing (snRNAs), a multitude of additional
non-protein-coding RNAs has been described in recent years.
According to their size, ncRNAs are categorized as small
(<200 bp) or long non-coding RNAs (lncRNAs, >200 bp).
SMALL NON-CODING RNAS
The group of short ncRNAs consists of microRNAs (miRNAs),
small interference RNAs (siRNAs), small nucleolar (snoRNAs),
and Piwi-interacting RNAs (piRNAs) (Zamore and Haley, 2005).
Of these, miRNAs have been best characterized in terms of
their function, regulation and role in multiple human diseases
such as cancer. Initiated by the discovery of the first miRNA,
lin-4 in Caenorhabditis elegans (Lee et al., 1993; Wightman
et al., 1993), large research efforts have led to a detailed
characterization of miRNA biogenesis and regulatory functions
in recent years (Ambros, 2004; Bartel, 2004; He and Hannon,
2004; Ebert and Sharp, 2012). Binding of miRNAs to specific sites
in their target transcripts, called miRNA recognition elements
(MRE), results in either transcript degradation or translational
inhibition (Lee et al., 1993; Shivdasani, 2006). Currently there
are just under 2,000 human high-confidence annotated miRNAs
(Kozomara et al., 2018), and it is believed that they collectively
regulate at least one third of the genome (Hammond, 2015).
Importantly, gene expression profiling studies have demonstrated
altered miRNA expression in a wide range of human diseases,
including cancer.
miRNAs AND CANCER
miRNAs have been shown to participate in cancer throughout the
various stages: from tumor origin, to immortalization, metastatic
steps and interactions with the host tissue (Saliminejad et al.,
2018), and they are able to regulate oncogenes and tumor
suppressor genes. In the clinical setting, miRNA expression
signatures are emerging as important diagnostic and prognostic
predictors (Cho, 2007; Kong et al., 2012; Hayes et al., 2014;
Drusco and Croce, 2017). Functional studies clearly support a
relevant role of certain miRNAs in cancer. However, a remaining
challenge is to understand the exact signaling pathways altered
by miRNA deregulation. Several factors contribute to this
complexity: (1) the 3′ UTR of a particular target gene contains
multiple MREs; (2) multiple MREs can act either alone or
cooperatively and (3) the same miRNA can regulate different
targets (Doench and Sharp, 2004; Grimson et al., 2007).
In addition to cell-type-specific gene expression profiles,
deregulation of miRNAs can result in tumor suppressive or
oncogenic effects in a context-dependent manner (Zhang et al.,
2007). Furthermore, the existence of feedback loops involving
certain transcription factors such as c-Myc, which is both a
regulator of miRNA expression and a target of miRNAs, adds
yet another layer of complexity to the role of miRNAs in cancer
(Jackstadt and Hermeking, 2015).
miRNA TRAFFICKING
While the main mechanism of action is to control mRNA
stability or translation in the cytoplasm, miRNAs can be found
in unexpected cellular compartments such as the nucleus,
mitochondria, and endoplasmic reticulum (Leung, 2015).
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They are also found in the extracellular space – this was first
described in 2008, when it was proposed that circulating miRNAs
may serve as biomarkers of certain cancers (Mitchell et al.,
2008). Since then, miRNAs have been discovered in various
extracellular environments including blood (Weber et al., 2010),
urine (Gidlof et al., 2011), saliva (Park et al., 2009; Patel et al.,
2011), and ascitic fluid (Husted et al., 2011). These findings
opened up two new fields of investigation on miRNA. First,
as they are easy to detect in body fluids, clinical research has
focused on the use of extracellular miRNAs as biomarkers as
an alternative, non-invasive method for diagnosis and disease
monitoring (Duttagupta et al., 2011; Ajit, 2012). Second, because
miRNAs are found in the extracellular space, it was proposed that
they may act not only in the cells in which they are transcribed
but also in neighboring cells. This intriguing idea of horizontal
transfer of genetic material subsequently gained major attention.
To date, five non-exclusive mechanisms of miRNA release from
donor cells have been proposed: (i) miRNA bound to RNA-
protein complexes (e.g., in complex with Argonaut) (Arroyo
et al., 2011; Turchinovich et al., 2011); (ii) transport via lipid or
lipoprotein particles (Rayner and Hennessy, 2013); (iii) vesicles
shed directly from the plasma membrane (Hunter et al., 2008;
Callis et al., 2009; Shefler et al., 2010; Jaiswal et al., 2012); (iv)
vesicles of endosomal origin (exosomes) (Valadi et al., 2007;
Skog et al., 2008; Rechavi et al., 2009) and (v) vesicles from
apoptotic bodies (Zernecke et al., 2009; Hergenreider et al.,
2012). Currently, the coexistence of these different forms of
miRNA transport is supported in the literature, but improved
biochemical methods and molecular tools with higher temporal
and spatial resolution are required to strengthen the evidence
(Tkach and Thery, 2016).
Many groups have clearly demonstrated that isolated
miRNA containing fractions (e.g., exosomes) from donor
cells are capable of inducing phenotypic alterations in
the recipient cells. However, studies on the underlying
mechanisms are rare thus far, and basic questions concerning
the amount of miRNA (signaling-like or enzymatic function)
or the type of miRNA [individual or pool of miRNA(s)]
remain unaddressed.
LONG NON-CODING RNAs
All RNAs longer than 200 nucleotides that are not translated
into proteins are collectively categorized as lncRNAs (Carninci
et al., 2005; Guttman et al., 2009; Ponting et al., 2009; Cabili
et al., 2011; Derrien et al., 2012; Housman and Ulitsky,
2016; Lagarde et al., 2017). Similarly to mRNAs, lncRNAs
are transcribed by RNA polymerase II and are often subject
to post-transcriptional modification like 5′ capping, 3′ poly-
adenylation and splicing (Quinn and Chang, 2016). Although
less well-studied than miRNAs, several thousand lncRNAs have
already been described, and thanks to technical advances in
RNAseq techniques and computational prediction methods,
the total number of lncRNAs identified continues to increase
(Quinn and Chang, 2016; Hon et al., 2017). Solely defined by
their length, lncRNAs constitute the largest class of ncRNAs
in the mammalian genome, and can be further categorized
into long intergenic ncRNAs (lincRNAs), antisense RNAs
(asRNAs), pseudogenes, and circular RNAs (circRNAs) (Quinn
and Chang, 2016; Lagarde et al., 2017). lncRNAs fulfill a variety
of functions by interacting with DNA, RNA and proteins,
and they may be described according to their mechanism of
action toward their interacting molecule as enhancers, decoys,
guides or scaffolds (Wang and Chang, 2011; Fok et al., 2017;
Kopp and Mendell, 2018).
The first unsupervised clustering analysis of individual
transcripts in different tissues revealed that 78% of lncRNAs
(in comparison to 19% of mRNAs) were expressed in a
tissue-specific manner (Cabili et al., 2011). As sequencing
techniques advanced, this specificity of expression has been
observed at the individual cell level, and even differential
cell-to-cell expression has been observed by Lv et al.
(2016); we could confirm this in our own (unpublished)
studies in the triple negative breast cancer cell line MB-
MDA231. In the field of cancer biology, lncRNA expression
profile has recently been proposed as a strong prognostic
factor and even as a therapeutic target (Chen et al., 2014;
Yarmishyn and Kurochkin, 2015).
Despite the growing catalog of lncRNAs, the majority of
detected transcription products remain functionally unanno-
tated. Gene function prediction based on sequence homology for
protein-coding genes is challenging (Ulitsky, 2016). Therefore,
lncRNA classification requires either specialized computational
tools or genome-wide functional studies as currently performed
by the use of gene knockout techniques (e.g., CRISPERi) (Gilbert
et al., 2013; Goyal et al., 2017).
lncRNAs IN CANCER
Differential expression of lncRNAs has been described in a
variety of pathological conditions including cardiovascular,
autoimmune, neurodegenerative diseases and particularly in
cancer (Walsh et al., 2014; Nguyen and Carninci, 2016; Zhang
et al., 2016; Aune et al., 2017; Bhan et al., 2017; Viereck and
Thum, 2017; Wan et al., 2017). The first reported lncRNA
with an aberrant expression in cancer was prostate cancer
associated 3 (PCA3) (Bussemakers et al., 1999), which was
identified via differential display analysis of transcripts in normal
human prostate cancer. PCA3 was the first FDA-approved
lncRNA-based biomarker for use in clinical practice. Since then,
it has proven a useful, non-invasive test for prostate cancer
(Wei et al., 2014). In subsequent years, many other lncRNAs
have been identified as having a highly predictive value in
the diagnosis of different cancers. Among those, deregulated
expression of the lncRNA HOTAIR, originally described in
breast cancer, is associated with cancer progression in 26
human tumor types (Gupta et al., 2010; Bhan and Mandal,
2015; Teschendorff et al., 2015). Recently, the application of
next-generation sequencing in a variety of different cancer
transcriptomes uncovered thousands of lncRNAs with aberrant
expression in different cancer types (Huarte, 2015). These
numbers increase further when single nucleotide polymorphisms
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(SNPs) that are associated with cancer are taken into account
(Freedman et al., 2011).
Regarding metastasis, some lncRNAs have been associated
with more aggressive, metastatic tumors and even with cancer cell
colonization to specific organ sites (Li et al., 2018). For example,
in colorectal carcinoma, expression of the lncRNA CCAT2
correlated with a higher incidence of liver metastasis (Ling et al.,
2013). Another example is the association of elevated levels of
HOTAIR with a higher incidence of liver metastasis in gastric
cancer (Zhang et al., 2015) and with brain metastasis in non-small
cell lung carcinoma (Nakagawa et al., 2013).
Despite the enormous number of lncRNAs described
as having aberrant expression in different cancer types,
to date, only a few have been functionally characterized
(reviewed in Huarte, 2015); existing studies have identified
tumor-suppressor and oncogenic functions of lncRNAs
(Prensner and Chinnaiyan, 2011; Huarte, 2015). In many
cases, the functional role of these lncRNAs has been linked
to well-known oncogenic pathways like p53 and c-myc or
participating in different steps of classical cancer processes
such as epithelial mesenchymal transition (EMT). Functional
analysis will probably expand with the recent application of the
CRISPR/Cas9 system, which will provide the tools required to
study the function of lncRNAs in genome-wide studies. These
unsupervised studies will be crucial to functionally annotate
the role of lncRNAs in cancer and shed further light on the
regulation of the underlying molecular events (Han et al., 2014;
Ho et al., 2015).
lncRNA AND miRNA INTERPLAY
Different lncRNAs are known to interact with DNA, RNA,
and proteins; therefore, the functions of the class of lncRNAs
appear to be pleiotropic, ranging from chromatin remodeling to
the regulation of transcription, splicing, and translation (Wang
and Chang, 2011; Fok et al., 2017; Kopp and Mendell, 2018).
A subclass of lncRNA has recently been shown to regulate gene
expression in trans by acting as miRNA “sponges” (Karreth et al.,
2011; Salmena et al., 2011; Tay et al., 2011; Karreth and Pandolfi,
2013; Su et al., 2013; Yoon et al., 2014; Ulitsky, 2018). These
lncRNAs belong to a group of RNAs named ceRNA (competitor
of endogenous RNA) (Tay et al., 2014; Thomson and Dinger,
2016; Zhong et al., 2018). While there is no unifying definition of
ceRNAs, their function as miRNA “sponges” minimally requires
their cytoplasmic localization and the presence of MRE in their
sequence. ceRNAs contain MREs for one or multiple miRNAs,
and binding is thought to sequester miRNAs and thereby enable
translation of endogenous miRNA targets (Figure 1).
In recent years, this concept has been described for the
expression of different genes involved in tumor progression (de
Giorgio et al., 2013; Cheng et al., 2015; Wang et al., 2016;
Song et al., 2017). An example of an oncogenic lncRNA is
UCA1, which controls the availability of miR-18a and thereby
determines the expression of the oncogene YAP1 (Zhu et al.,
2018; Figure 2A). In contrast, the tumor suppressor gene PTEN
is regulated by the lncRNA CCAT2 by acting as a competing
FIGURE 1 | Modified version of the central dogma of molecular biology. The
classical “DNA-RNA-protein” pathway is extended by functional role
of ncRNAs.
FIGURE 2 | Competing lncRNAs (ceRNAs) in cancer. LncRNAs can act either
as oncogenes (A) or as tumor suppressor (B) as exemplified by the role UCA1
and CASC2. A detailed literature survey of the reported roles ceRNAs in
cancer is summarized in Supplementary Table S1.
RNA for miR-21 (Figure 2B; Xie et al., 2017). In recent years,
many more ceRNAs have been described in cancer. We have
summarized the known lncRNA/miRNA/mRNA combinations
in Supplementary Table S1.
In addition to sequestering miRNAs, lncRNAs have also been
reported to compete with miRNAs by binding directly to mRNAs
(Faghihi et al., 2010). miRNAs have been reported to induce
destabilization of lncRNAs, yet some lncRNAs contain miRNAs
precursors (Cui et al., 2016). This suggests a complex interplay
between lncRNAs and miRNAs, which ultimately determines
stability and translation of protein-coding mRNAs. Notably,
recent studies have revealed that ceRNAs have significant roles in
cancer pathogenesis (Cheng et al., 2015; Wang et al., 2016). For
example, alterations in the expression of key factors in oncogenic
signaling pathways, like BRAF, have been linked to changes
in the level of ceRNAs (Ergun and Oztuzcu, 2015; Karreth
et al., 2015). We are just starting to understand these complex
molecular interactions, their place in functional regulatory
networks controlling cellular processes, and their implications in
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cancer (Liz and Esteller, 2016; Yang et al., 2016; Cao et al., 2017;
Chan and Tay, 2018).
PROPOSAL: TISSUE-SPECIFIC
INTERPLAY BETWEEN miRNA
AND lncRNA SUPPORTS
CONTEXT-DEPENDENT
CELL SIGNALING
Currently, the mechanisms involved in cancer origin and
progression have been elaborated according to the alterations
found in protein-coding genes, barely 2% of the translated
genome. Following this approach, most of the described
alterations merge into few biochemical routes such as the
PI3K/AKT/mTOR or RAS/MAPK pathways. However, the
outcome of these alterations is sometimes tissue-specific and
cell-context-dependent. It is, for example, still unclear how
certain oncogenic mutations progress to tumor formation only
in a particular set of tissues. There are clear examples with
germline mutations in genes like adenomatous polyposis coli
(APC), cadherin 1 (CDH1), BRCA1, von Hippel-Lindau tumor
suppressor (VHL), and ataxia telangiectasia mutated (ATM)
which are causative for the development of cancer in specific
types of tissue (Schneider et al., 2017). Another paradigmatic
example is the initial good response to specific inhibitors in
melanomas harboring the BRAFV600E mutation, compared to the
protumor effect of the same inhibitors in colon adenocarcinomas
carrying similar BRAF mutations (Prahallad et al., 2012; Sclafani
et al., 2013). Finally, the development of metastases in different
types of cancer is often restricted to certain organs (organotropic
metastasis), and even clonal subpopulations within the primary
tumor display preferences for certain organs (Obenauf and
Massague, 2015).
Therefore, in addition to the classical oncogenic signaling
pathways (PI3K/AKT/mTOR or RAS/MAPK), additional layers
of regulation must exist, to explain tissue- and organ-specific
processes. We hypothesize that these cell-type-specific outcomes
may be caused by interplay between lncRNAs and miRNAs.
Building on the concept of ceRNAs, the tissue and cell-type-
specific expression of lncRNAs might be a key mechanism
to support tissue-specific regulation of oncogenic signaling
pathways. In this sense, the translational profile (i.e., proteome)
of miRNA-regulated mRNAs can be controlled by the cell-
type-specific expression of lncRNAs. Consequently, the interplay
between lncRNAs and miRNAs might affect signaling cascades by
regulating the abundance of proteins within these pathways in a
cell-type-specific manner (Figure 3A).
This core mechanism, acting on the intracellular level, can
also be extended to communication between different cells.
This is because miRNAs not only act in the cells in which
they are transcribed but can also be transferred into different
cells (intercellular level). In this regard, the interplay between
miRNAs and lncRNAs suggests many parallelisms to ligand–
receptor interactions. Ligands like cytokines, hormones and
growth factors are released as soluble factors by the donor cell,
FIGURE 3 | Proposal on the role of tissue specific ceRNAs in cancer
(A) Tissue specific expression of lncRNAs can induce malignant
transformation in cells expressing an equal set of miRNAs and mRNAs.
(B) Tissue specific response to secreted miRNAs dependent on the
expression profile of lncRNAs.
selectively interact with the target cell receptors and activate
signaling cascades which ultimately alter the phenotype of the
target cell. miRNAs have been shown to be released into the
extracellular space, and lncRNAs are expressed in an organ-,
tissue- or cell-type-specific manner. As described above, the
abundance of lncRNAs may ultimately determine the effect of
miRNAs on the expression of protein-coding genes. Therefore,
as occurs in the ligand-receptor model, exposure to the same
miRNA may result in cell-type-specific alterations dependent on
the expression of lncRNAs (Figure 3B).
In summary, the interplay between lncRNAs and miRNAs
at an intra- and intercellular level may provide a framework
for understanding context-specific phenomena in cancer. In the
following section, we will exemplify these putative mechanisms
in two concrete cases.
INTRACELLULAR INTERPLAY BETWEEN
lncRNAs AND miRNAs – BRAFV600E IN
COLON ADENOCARCINOMA VS
MELANOMA
Transduction of a signal from an activated receptor is dependent
on the levels of kinases and phosphatases in these pathways and
is regulated by positive and negative feedback loops. Alterations
in the stoichiometry of factors involved in signaling cascades
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FIGURE 4 | The potential role of lncRNAs in the failure of Vemurafenib in the treatment of colon cancer. Upper panel: BRAFV600E mutation induces malignant
transformation in melanoma and colon cancer. Lower panel (left): treatment with Vemurafenib inhibits malignant transformation in melanoma. Bypassing the inhibition
of BRAFV600E by Vemurafenib might be prevented by miRNAs (e.g., miR-34a or miR-218a) inhibiting the expression of ARAF (Lal et al., 2011; Agarwal et al., 2015).
Lower panel (right): sequestering of the ARAF controlling miRNA(s) by lncRNAs in colon cancer enables the bypass of Vemurafenib inhibition, resulting in
malignant transformation.
can be crucial for the ultimate cellular effect. A paradigmatic
example for such alterations in the same oncogenic pathway
is described for the BRAFV600E mutation. While treatment of
BRAFV600E–bearing tumors with BRAF inhibitors has a good
response in melanomas, a protumor effect has been described
in colon adenocarcinomas. It has been proposed that the local
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feedback in the different cell-signaling pathways could partly
explain this unexpected contradictory effect (Schneider et al.,
2017). In this respect, miRNAs have been described as key
players in fine-tuning the expression of proteins involved in
the Ras/Raf signaling pathway (reviewed in Masliah-Planchon
et al., 2016). However, the expression of the majority of these
miRNAs is not specific for single tissues; therefore, additional
layers of regulation must exist, to explain the different responses.
We propose that the tissue-specific interplay between ncRNAs
might partly explain the different sensitivity to BRAF inhibitors
in colon adenocarcinoma and melanoma harboring the same
oncogenic mutation in BRAF (Figure 4).
INTERCELLULAR INTERPLAY BETWEEN
lncRNAs AND miRNAs –
ORGANOTROPIC METASTASIS
miRNAs are released into the extracellular space and transferred
to target cells. lncRNAs (the “receptors”) show organ-, tissue-
and cell-type-specific expression. Binding of miRNAs to lncRNAs
(akin to a ligand-receptor complex) occurs via a sequence-
specific MRE within the lncRNA. Finally, this interaction
results in miRNA sequestration and/or degradation of miRNA
or lncRNA. As the ligand-receptor model would predict,
these interactions should result in the activation of signaling
cascades enabling significant alterations in biochemical and
cellular functions.
Applying this model to cancer, the mechanisms
underlying organotropic metastasis might be explained
in part by the interplay between miRNAs and lncRNAs.
Even though there is no direct experimental evidence
for this hypothesis, there are theoretical possibilities for
how this interplay could contribute to the development of
site-specific metastasis.
High levels of secreted miRNAs from cancer cells have been
reported for almost all types of tumor cells. Upon arrival of
a disseminated tumor cell to a distant tissue (e.g., lung, bone,
or brain), these miRNAs are first taken up by tissue-specific
endothelial cells. Transfer of miRNAs to endothelial cells in turn
has been shown to alter the expression of proteins required
for maintenance of the endothelial barrier (Zhou et al., 2014;
Tominaga et al., 2015). Therefore, the expression profile of
competing lncRNAs within endothelial cells might determine if
the barrier function can be sustained in the presence of exogenous
miRNAs, and metastasis will be favored in organs in which
ceRNAs are absent (Figure 5).
In addition, aberrant expression of lncRNAs has been
reported in different tumor types, and differential cell-to-
cell expression has even been observed in certain tumor
types (Lv et al., 2016). Therefore, the presence of sponging
lncRNAs might alter (a) the miRNA secretome of tumor cells,
and (b) the responsiveness to secreted miRNAs from other
cells. The latter case in particular might account for clonal
populations of tumor cells with site-specific patterns of metastasis
(Obenauf and Massague, 2015).
FIGURE 5 | The potential role of lncRNAs in organotropic metastasis. Cancer
cell secreted miRNA (e.g., miR-105 and miR181c prevent the expression of
proteins with barrier function in endothelial cells Zhou et al., 2014; Tominaga
et al., 2015). The presence of tissue specific competing lncRNAs can
sequester those miRNAs (lung and brain), the endothelial barrier is maintained
and cancer cells are not able to invade.
It is tempting to speculate that the interplay between
lncRNAs and miRNAs combined with the tissue- or clone-
specific expression of lncRNAs might favor the formation
of metastatic niches in an organ- or tissue-specific manner.
However, future detailed studies will be required to prove
this hypothesis.
FUTURE DIRECTIONS
In our opinion, the continuous accumulation of large amounts of
data by RNAseq of whole cancer transcriptomes or extracellular
miRNAs might be only partially helpful to move forward.
We propose exploring the mechanistic basics in cell-culture-
based systems or even model organisms with a reduced
complexity. Models derived from these studies could later be used
to predict how the extracellular miRNA composition combined
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with a distinct set of intracellular lncRNAs might impact on
disease progression.
In summary, current limitations in our understanding on
the molecular mechanisms of cancer might be due to the fact
that, until now, only 2% of the genome has been taken into
account. Therefore, future studies should aim at expanding our
current view of cancer by including the role of ncRNAs in
the interpretation of cancer as a multifactorial disease. The
proposed model, combining lncRNA-miRNA interactions with
intercellular communication might be particularly helpful in
understanding the tissue-specificity of many cancers, hitherto
one of the least understood phenomena of cancer.
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